Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|March 19, 2026

The BioPharm Brief: Investments in Next-Gen Modalities Drive Oncology and Metabolic Therapy Development

Today’s podcast dives into Series A funding for T‑cell engagers and the advancement of multi-agonist metabolic therapies, which highlight innovation and platform-driven strategies in current biopharma pipelines.

Welcome to The BioPharm Brief, your daily snapshot of key developments in biopharmaceutical research, innovation, and clinical progress. Today’s update highlights fresh funding for T‑cell engager platforms and continued momentum in multi‑agonist metabolic therapy development.

First up, Excalipoint Therapeutics has just launched with a $68.7 million Series A financing to advance its T‑cell engager platform initiatives. The company’s strategy centers on novel bispecific and multispecific constructs designed to recruit T cells to cancer cells more effectively, with the goal of improving anti‑tumor immune responses while managing safety and specificity. Support from this funding round is expected to accelerate preclinical programs and expand operational capacity as Excalipoint scales its platform toward early clinical proof‑of‑concept studies. The financing reflects robust investor interest in next‑generation immuno‑oncology platforms tailored for solid tumors, where conventional approaches have historically shown variable clinical success.

In other news, Eli Lilly and Company is advancing its triple‑agonist candidate, retatrutide, in the treatment of type 2 diabetes. Retatrutide engages three metabolic hormone pathways simultaneously—GLP‑1, GIP, and glucagon receptors—with the aim of improving glycemic control and supporting weight loss through coordinated metabolic regulation. Clinical data from ongoing studies have underscored the potential for durable benefits across key cardiometabolic endpoints, reinforcing industry confidence in multi‑agonist strategies that target multiple receptors to achieve enhanced therapeutic outcomes. The continued development of retatrutide aligns with a broader shift in metabolic disease research toward integrated hormonal modulation to address complex pathophysiology beyond glucose lowering alone.

These developments illustrate how strategic financing and innovative molecular design are driving forward next‑generation modalities across both oncology and metabolic disease spaces.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments

  • Excalipoint’s $68.7 M funding will support expansion of T‑cell engager platforms targeting solid tumors.
  • Lilly’s triple‑agonist retatrutide continues advancing as a promising metabolic therapy for type 2 diabetes.
  • Investment and multispecific strategies remain central to emerging biopharma innovation.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more